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Correction to: British Journal of Cancer (2009) 100, 1444–1451.
doi:10.1038/sj.bjc.6605020
Upon publication of this paper in 2009, the authors noticed two
errors – one in the abstract and one within the Results section.
On page 1444 (Abstract), the seventh sentence should read
as follows:
‘In a combining analysis, patients with a CXCR7
high/CXCR4
high
tumour had a significantly shorter DFS and OS than patients with a
CXCR4
low/CXCR7
low tumour’.
On page 1447 (Results), the first sentence of the section
entitled ‘CXCR4 and CXCR7 coexpression and patients outcome’
should read as follows:
‘Interestingly, patients with CXCR4
low/CXCR7
low tumour
expression have a significantly prolonged DFS and OS than those
patients with a CXCR4
high/CXCR7
high tumour expression
(Figure 3C; median DFS: 15.80 months (95% CI: 10.43–21.17) vs
7.62 (2.97–12.27), P¼0.037; median OS: not reached vs 9.69
(95% CI: 5.13–14.07), P¼0.001)’.
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